CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that Curis’ collaborator Genentech, Inc. and the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD) are planning to enter into a Cooperative Research and Development Agreement (CRADA) which will allow the NCI to explore GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, in a number of cancer indications.
